Treat canine osteoarthritis (OA) pain and inflammation with confidence through every stage of OA and help dogs enjoy moments that matter with their families.
Unfortunately, too many dogs are suffering in silence with unrecognized or untreated canine osteoarthritis (OA). To provide the highest quality of care, it’s time to evolve the approach to recognizing, diagnosing and managing canine OA through early intervention and treatment.
Canine OA is a progressive disease, and signs of pain may be subtle or overlooked
Canine OA is often conformational in nature and can affect young dogs, so early detection and diagnosis is key1
Start multimodal treatment of OA as soon as the dog is diagnosed
Canine OA is the most common cause of chronic pain in dogs, affecting 1 in 4 adult dogs in the US.2
Early signs of OA can be hard to distinguish, leading to delayed diagnosis and chronic pain later in life.
Canine OA, the most common cause of chronic pain in dogs3, is often conformational in nature so it can develop at a young age.1Learn about the Condition
Canine OA is a progressive disease. It can affect dogs during any stage of life, interrupting the special moments shared with their owners.Learn about the Stages
Recognizing the signs of OA and engaging the pet owner throughout the process will help you diagnose accurately and early, so you can provide high-quality care to your patients.Learn about the Signs
A multimodal treatment approach begins with pain management using an NSAID.Treating Canine OA
Experience the joy of providing effective canine OA pain relief and improving the lives of patients.Watch Inspiring Stories
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.